Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.38 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499160 | 1.00 | CA2 (0.41) | CA2ADRA1DSLC10A2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL1002826 | 0.98 | CA2 (0.42) | CA2ADRA1DSLC10A2ANPEP | |
| SCHEMBL14275866 | 0.89 | ADRA1D (0.34) | CA2ADRA1DSLC10A2SLC6A2SLC6A3 | |
| SCHEMBL10192537 | 0.80 | SLC6A2 (0.38) | CA2SLC10A2SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL30989920 | 0.78 | SLC6A2 (0.37) | SLC10A2SLC6A2SLC6A4ANPEPHTR2A | |
| Hydrochloric Acid SCHEMBL30989811 | 0.78 | SLC6A2 (0.37) | SLC10A2SLC6A2SLC6A4ANPEPHTR2A | |
| SCHEMBL2906599 | 0.77 | SLC6A2 (0.33) | SLC6A2SLC6A3SLC6A4HTR2A | |
| SCHEMBL24090474 | 0.77 | ADRA1D (0.38) | CA2ADRA1DSLC10A2SLC6A2SLC6A4 | |
| SCHEMBL12900511 | 0.77 | ADRA1D (0.38) | CA2ADRA1DSLC10A2SLC6A2SLC6A4 | |
| SCHEMBL12651546 | 0.77 | ADRA1D (0.38) | CA2ADRA1DSLC10A2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1434485-B1 | NICOTINIC ACID-HETEROCYCLYL-AMIDES AND ANALOGOUS PYRIMIDINE DERIVATIVES FOR USE AS PESTICIDES | MERIAL LTD (US) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CA2 3402/4885ADRA1D 3446/4885SLC10A2 4110/4885 |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | CA2 1906/4885ADRA1D 6/4885SLC10A2 831/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | CA2 4035/4885ADRA1D 3403/4885SLC10A2 3987/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | CA2 3106/4885ADRA1D 3340/4885SLC10A2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.